TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05410548

Intervention type: OTHER
Group type: OTHER
Intervention: Standard-of-Care
Description: Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care
Description: Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Screening
Description: Participants will complete the following self-report questionnaires: (a) the Patient Health Questionnaire-9 item, which may suggest major depression and/or suicidal ideation; and (b) the STarT Back Screening Tool, a 6-item tool used to screen for greater than low-risk for persistent, bothersome and disabling low back pain. Prosthetists will perform palpation of the contralateral dorsalis pedis and posterior tibial pulses and note presence or absence, as an indicator of peripheral arterial disease. Prosthetists will evaluate protective sensation of the contralateral foot through Semmes-Weinstein monofilament assessment of the great toe, the 1st and 3rd metatarsal heads. The prosthetist will record the results in a letter that is sent to the patient's primary care provider, and provide a copy of the letter to the patient after discussing the results for each of the screens.
Study: NCT05513014

Intervention type: DRUG
Intervention: Secukinumab
Description: Patients with Psoriasis who initiated Secukinumab
Study: NCT05765903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: * Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: * Additional educational training using computer tablet devices, such as iPads.~* Focus on readmission risk.~* Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH).
Study: NCT05708742

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline solution
Description: The control group underwent the same procedure but had a sham injection (20 ml of saline).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Needle
Description: A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
Study: NCT06540950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Vinorelbine is administered orally at 60mg per square meter per week by body surface area before radiotherapy and continued to be administered at 30mg per square meter per week during radiotherapy until the end of radiotherapy. Within 6 weeks after the end of radiotherapy, there are no serious side effects, and immune checkpoint inhibitors monotherapy can be performed.
Study: NCT05997355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 600Mg Tab
Description: A single preoperative dose of gabapentin 600mg
Study: NCT05801237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0116&PE0105
Description: This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor
Study: NCT06526936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Information about diabetic foot care
Study: NCT05977647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Oral Capsule
Description: Patient will be enrolled in one of study arm through randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Oral Capsule
Description: Patient will be enrolled in one of study arm through randomization.
Study: NCT05504200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder and Pelvic Floor Muscle Training
Description: The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
Study: NCT05521737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
Study: NCT06054217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle of TP-03
Description: The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle of TP-03
Description: The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle of TP-03
Description: The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
Study: NCT06155630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mandibular implant-overdenture
Description: Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
Study: NCT06217120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT06549751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-601
Description: Cellular Therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-601
Description: Cellular Therapy
Study: NCT04902365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurofeedback
Description: (based on real-time functional magnetic resonance signals)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: neurofeedback
Description: (based on real-time functional magnetic resonance signals)
Study: NCT06155630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mandibular implant-overdenture
Description: Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
Study: NCT06547970

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational intervension
Description: an educational intervention about the disease, symptoms \& how to deal with these symptoms, foot care, life style like sport and nutritional advices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervension
Description: an educational intervention about the disease, symptoms \& how to deal with these symptoms, foot care, life style like sport and nutritional advices
Study: NCT05120739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% CHX cloths
Description: skin preparation in 2% CHX cloths
Study: NCT05481476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250mg, qd, po, 21 days for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, ivgtt, d1, 21 days for a cycle, up to 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG
Description: nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
Study: NCT05738681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
Study: NCT06405945

Intervention type: GENETIC
Intervention: PCR and sequence
Description: sequence the mutatation SNPs
Study: NCT04871503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899 Buttocks
Description: The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899 Buttocks
Description: The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
Study: NCT06070948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet
Study: NCT05074758

Intervention type: DIAGNOSTIC_TEST
Intervention: alveolar dead-space quantification
Description: measurement of alveolar dead-space based on volumetric capnography

Intervention type: DIAGNOSTIC_TEST
Intervention: alveolar dead-space quantification
Description: measurement of alveolar dead-space based on volumetric capnography

Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation activation and impaired fibrinolysis explorations
Description: blood sampling:~* Fibrinolytic components~* NETs components~* Elastase-derived fragments of proteins of interest

Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation activation and impaired fibrinolysis explorations
Description: blood sampling:~* Fibrinolytic components~* NETs components~* Elastase-derived fragments of proteins of interest

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial activation / endothelial senescence
Description: circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial activation / endothelial senescence
Description: circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
Study: NCT04982081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hiPSC-CM therapy
Description: 20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hiPSC-CM therapy
Description: 20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
Study: NCT06547983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutritional advice
Description: Participants in the intervention group received personalized nutrition advice based on their dietary habits, weight, anthropometric data and physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutritional advice and food boxes
Description: Participants in the intervention plus group received the personalized nutrition advice while also receiving food boxes which are composed based on the personalized nutritional advice.
Study: NCT05859386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness maintenance program
Description: 1. Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~2. Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~3. Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice.
Study: NCT05406791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIRA App
Description: Support from coach and using the VIRA app

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mood Education App
Description: Support from mood education app
Study: NCT06001034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusion training
Description: Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.
Study: NCT04822545

Intervention type: OTHER
Group type: OTHER
Intervention: referral to comprehensive weight management clinic
Description: Patients will receive a referral for outpatient CWM clinic, with a message sent to the CWM clinic scheduler, prior to hospital discharge.~At six months after discharge, the patient will receive a phone call from the investigators to ascertain whether they were able to go to the CWM clinic and about their experience.
Study: NCT05764148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral activation
Description: Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring.~Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: behavioral activation
Description: Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring.~Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions.
Study: NCT06286865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Easy-ICD
Description: Easy-ICD is an AI-based computer-assisted clinical coding (CAC) system that helps clinical coder assign ICD-10 codes to clinical notes such as discharge summaries.
Study: NCT06405945

Intervention type: GENETIC
Intervention: PCR and sequence
Description: sequence the mutatation SNPs

Intervention type: GENETIC
Intervention: PCR and sequence
Description: sequence the mutatation SNPs

Intervention type: GENETIC
Intervention: PCR and sequence
Description: sequence the mutatation SNPs
Study: NCT05152225

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Brain MRI performed routinely in patients with EI

Intervention type: DIAGNOSTIC_TEST
Intervention: digital subtraction angiography (DSA)
Description: Digital Subtraction Angiography (DSA) performed routinely in patients with EI
Study: NCT05357378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip Innovation Technology Reverse Hip Replacement System
Description: Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.
Description: Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~* DePuy Synthes Corail® Total Hip System in combination with Pinnacle® Complete Acetabular Hip System.~* Zimmer Biomet Taperloc® Complete Hip System in combination with G7® Acetabular System.~* Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~* Smith \& Nephew Anthology® Total Hip System in combination with R3® Acetabular System.
Study: NCT06531980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modi
Description: The Modi course, an eight-week mobile application intervention for adolescents with anxiety symptoms, is based on cognitive therapy. Guided by a rule-based chatbot named Anna, users navigate through predefined options and responses, learning about anxiety and recording their challenges. The app includes animated videos, illustrations, and audio files to enhance engagement. Modi consists of six chapters, with a focus on psychoeducation, the cognitive triangle, and exposure exercises. Participants receive guidance from two Modi therapists who provide weekly support via messages and scheduled phone calls, ensuring personalized assistance and addressing any issues throughout the course.
Study: NCT05679362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online brief CBT intervention
Description: Cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online brief CBT intervention
Description: Cognitive behavioral therapy
Study: NCT05918380

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PAL2
Description: Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education.

Intervention type: OTHER
Group type: OTHER
Intervention: CINEMA
Description: High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
Study: NCT03927066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
Study: NCT05313425

Intervention type: OTHER
Intervention: Ectohylo (R) eye drops
Description: using Ectohylo eye drops post operative after PRK in the right eyes of the patients
Study: NCT05567874

Intervention type: OTHER
Intervention: Nosocomial SARS-COV 2 Infection proportion
Description: Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

Intervention type: OTHER
Intervention: Nosocomial SARS-COV 2 Infection proportion
Description: Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

Intervention type: OTHER
Intervention: Nosocomial SARS-COV 2 Infection proportion
Description: Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
Study: NCT05385679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Extraction of lower third molar
Description: The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Extraction of lower third molar
Description: The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.